Cancer Anorexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Cancer Anorexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major cancer anorexia markets are expected to exhibit a CAGR of 10.48% during 2024-2034.

The cancer anorexia market has been comprehensively analyzed in IMARC's new report titled "Cancer Anorexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer anorexia, also known as cancer-related anorexia-cachexia syndrome, refers to a complex and multifactorial condition characterized by a significant loss of appetite and unintended weight loss in individuals suffering from cancer. The ailment can adversely impact the quality of life and overall well-being of cancer patients, leading to increased morbidity as well as reduced tolerance to cancer treatments. Individuals suffering from the condition may have a decreased desire to eat, an aversion to certain foods, early satiety, and a significant decline in food intake. Various other symptoms may include malnutrition, altered taste perception, fatigue, weakness, etc. Diagnosing cancer anorexia involves a comprehensive investigation by healthcare professionals, typically oncologists, dietitians, and palliative care specialists. The diagnosis is based on clinical evaluation, including the patient's medical history, physical examination, and assessment of symptoms related to appetite loss and unintended weight loss. Several laboratory tests, such as blood work and nutritional markers, may be conducted to assess nutritional status as well as identify any underlying medical conditions contributing to anorexia. Additionally, questionnaires and interviews may be utilized to determine the patient's appetite, dietary intake, and emotional well-being.

The rising cases of tumor formation, which can produce substances that alter the body's metabolism, increase energy expenditure, and lead to appetite suppression, are primarily driving the cancer anorexia market. Besides this, the escalating utilization of cancer treatments, like chemotherapy and radiation therapy, that can have direct effects on the gastrointestinal tract, causing nausea, vomiting, and altered taste perception, thereby reducing food intake, is creating a positive outlook for the market. Moreover, the widespread adoption of appetite stimulants for increasing appetite, supporting weight maintenance, and improving overall nutritional status is further bolstering the market growth. Apart from this, the inflating application of novel taste alteration therapies, such as zinc supplementation and taste-modifying agents, since they aim to restore the sense of taste and enhance food intake in cancer patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of probiotics, prebiotics, and fecal microbiota transplantation to reinstate gut microbial balance, reduce inflammation, and improve nutrient absorption, thus potentially alleviating anorexia-related symptoms, is expected to drive the cancer anorexia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cancer anorexia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cancer anorexia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer anorexia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer anorexia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer anorexia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cancer anorexia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the cancer anorexia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cancer anorexia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cancer anorexia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cancer anorexia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer anorexia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer anorexia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cancer anorexia across the seven major markets?
What is the size of the cancer anorexia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cancer anorexia?
What will be the growth rate of patients across the seven major markets?

Cancer Anorexia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cancer anorexia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer anorexia market?
What are the key regulatory events related to the cancer anorexia market?
What is the structure of clinical trial landscape by status related to the cancer anorexia market?
What is the structure of clinical trial landscape by phase related to the cancer anorexia market?
What is the structure of clinical trial landscape by route of administration related to the cancer anorexia market? Show more